SR9011

SR9011

Systematic (IUPAC) name
3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)-N-pentylpyrrolidine-1-carboxamide
Identifiers
CAS Number	1379686-29-9
PubChem	CID 57394021
ChemSpider	28487552
ChEMBL	CHEMBL1961797
Chemical data
Formula	C23H31ClN4O3S
Molar mass	479.03524 g/mol
SMILES CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc3ccc(s3)[N+](=O)[O-])C1
InChI InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29) Key:PPUYOYQTTWJTIU-UHFFFAOYSA-N

SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC₅₀) = 790 nM for Rev-Erbα and IC₅₀ = 560 nM for Rev-ErbAβ.^[1]

See also

• GW501516
• SR9009

References

1. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature 485 (7396): 62–8. doi:10.1038/nature11030. PMC 3343186. PMID 22460951. Lay summary – Nature Magazine.